Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily, Mid-Day, 11/3/11, a coin flip for markets with EU issues not in control

The 6 W’s: Who, what, where, when, why and what of it …

 

US stocks rose again Thursday but traders remained on edge tracking any news from Europe.

Mid-Day: The NASDAQ is UP +25.45 (+0.96%) to 2,665.43. The Dow is UP +117.76 (+0.99%) to 11,953.80.

Mid-Day Movers: Aastrom (ASTM), BioMimetic (NASDAQ:BMTI), BioTime (AMEX: BTX), Cytori (NASDAQ:CYTX), Dendreon (NASDAQ:DNDN), Geron (NASDAQ:GERN), ImmunoCellular (OTC BB: IMUC), Pluristem (NASDAQ:PSTI) and StemCells (STEM).

What’s new in the regenerative medicine/stem cell market …

Verastem files for $50M IPO: focused on treating cancer by targeting cancer stem cells, on Thursday filed intentions for an initial public offering of stock that could raise up to $50M.    http://www.scimitarequity.com/blog/2011/11/03/verastem-files-for-50m-ipo

Pluristem (PSTI) P1 Trials met All Endpoints: Positive 12-Month Data from the Use of PLX-PAD for the Treatment of Critical Limb Ischemia (NYSE:CLI). http://www.scimitarequity.com/blog/2011/11/03/pluristem-psti-p1-trials-met-all-endpoints 

California institute joins stem cell consortium: The La Jolla Institute for Allergy & Immunology in California has joined the Sanford Consortium for Regenerative Medicine. The consortium this month is expected to open a collaborative research facility with the goal of improving human health through stem cell studies. http://www.lajollalight.com/2011/10/31/la-jolla-institute-joins-stem-cell-consortium

New method makes cancer cells self-destruct: Researchers at the Baylor College of Medicine inHouston have developed a method to help facilitate cancer treatment. The method combines a certain gene with a transplanted cell, and a drug called AP1903 triggers the cell to self-destruct among harmful cells. The findings could be used in other therapies, including with embryonic stem cells, researchers wrote in the New England Journal of Medicine.

First true induced pluripotent stem cell (iPSC) patent issued by the USPTO: There are a number of U.S. companies and academic research centers developing iPSC-related products for drug testing and clinical uses. Among the 90 or so iPSC-related patent applications pending, the United States Patent and Trademark Office (USPTO) issued the first true iPSC patent on 11/1/11. http://www.nixonpeabody.com/publications_detail3.asp?ID=4101&name=Intellectual_Property_Alert

New York Academy of Sciences Symposium on Advances in Adult Stem Cell Therapy in Tissue Repair for Cardiovascular Diseases to Feature Aastrom Biosciences: Researchers to Review Recent Preclinical and Clinical Findings on Use of Cellular Therapies Derived From Bone Marrow Stem Cells to Treat Chronic Cardiovascular Disease. ASTM  will feature researchers from Aastrom Biosciences and other research leaders in adult stem cell therapy. The symposium will take place at the New York Academy of Sciences at 7 World Trade Center,250 Greenwich St., 40th floor, New York, NY on Wednesday, 11/30/11, from 12:30 to 4:30 pm.